These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32942298)

  • 21. Association between cardiac autonomic function and physical activity in patients at high risk of sudden cardiac death: a cohort study.
    Sun X; Zhao S; Chen K; Hua W; Su Y; Liu X; Xu W; Wang F; Fan X; Dai Y; Liu Z; Zhang S
    Int J Behav Nutr Phys Act; 2021 Sep; 18(1):128. PubMed ID: 34544427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.
    Bansal N; Szpiro A; Reynolds K; Smith DH; Magid DJ; Gurwitz JH; Masoudi F; Greenlee RT; Tabada GH; Sung SH; Dighe A; Go AS
    JAMA Intern Med; 2018 Mar; 178(3):390-398. PubMed ID: 29404570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Effect of Body Mass Index in Patients With an Implantable Cardioverter-defibrillator for Primary Prevention of Sudden Death.
    González-Cambeiro MC; Rodríguez-Mañero M; Abellas-Sequeiros A; Moreno-Arribas J; Filgueira-Rama D; González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):990-992. PubMed ID: 27480908
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry.
    Kipp R; Hsu JC; Freeman J; Curtis J; Bao H; Hoffmayer KS
    Heart Rhythm; 2018 Jun; 15(6):847-854. PubMed ID: 28987459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-Correlations between Scientific Physical Fitness, Body Mass Index Distribution, and Overweight/Obesity Risks among Adults in Taiwan.
    Hung CT; Lee PF; Lin CF; Ho CC; Chen HL; Hsieh JW; Lin IT; Kuo HC; Lin YT; Chen YT
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556941
    [No Abstract]   [Full Text] [Related]  

  • 27. The Heart Failure Overweight/Obesity Survival Paradox: The Missing Sex Link.
    Vest AR; Wu Y; Hachamovitch R; Young JB; Cho L
    JACC Heart Fail; 2015 Nov; 3(11):917-26. PubMed ID: 26454846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life outcome of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry.
    Biffi M; Ammendola E; Menardi E; Parisi Q; Narducci ML; De Filippo P; Manzo M; Stabile G; Potenza DR; Zanon F; Quartieri F; Rillo M; Saporito D; Zacà V; Berisso MZ; Bertini M; Tumietto F; Malacrida M; Diemberger I
    Europace; 2019 Oct; 21(10):1527-1536. PubMed ID: 31209482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study.
    Dubner S; Valero E; Pesce R; Zuelgaray JG; Mateos JC; Filho SG; Reyes W; Garillo R
    Ann Noninvasive Electrocardiol; 2005 Oct; 10(4):420-8. PubMed ID: 16255752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of Body Mass Index on Recurrence of Ventricular Arrhythmia, Mortality in Defibrillator Recipients With Ischaemic Cardiomyopathy.
    Samanta R; Narayan A; Pouliopoulos J; Kovoor P; Thiagalingam A
    Heart Lung Circ; 2020 Feb; 29(2):254-261. PubMed ID: 30922553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry.
    Mazimba S; Holland E; Nagarajan V; Mihalek AD; Kennedy JLW; Bilchick KC
    Int J Obes (Lond); 2017 Aug; 41(8):1164-1168. PubMed ID: 28209971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity paradox in associations between body mass index and diabetes-related hospitalization and mortality in patients with type 2 diabetes: Retrospective cohort studies.
    Lin CC; Li CI; Liu CS; Lin WY; Lin CH; Chiang JI; Yang SY; Li TC
    Diabetes Metab; 2019 Dec; 45(6):564-572. PubMed ID: 30858146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Joint impact of body mass index and physical capacity on mortality in patients with systolic heart failure.
    Zafrir B; Salman N; Amir O
    Am J Cardiol; 2014 Apr; 113(7):1217-21. PubMed ID: 24513473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation of Body Mass Index to Long-Term Survival After Cardiac Resynchronization Therapy.
    Grandin EW; Wand A; Zamani P; Rame JE; Verdino RJ
    Am J Cardiol; 2016 Dec; 118(12):1861-1867. PubMed ID: 27823599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.
    Akoudad S; Dabiri Abkenari L; Schaer BA; Sticherling C; Levy WC; Jordaens L; Theuns DA
    Am J Cardiol; 2017 May; 119(9):1414-1420. PubMed ID: 28267958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis.
    Sun WP; Li CL; Guo JC; Zhang LX; Liu R; Zhang HB; Zhang L
    Heart Fail Rev; 2016 Jul; 21(4):447-53. PubMed ID: 27043219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.